{"id":"W2096928121","doi":"10.1186/1742-6405-7-30","title":"Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)","year":2010,"lang":"en","type":"article","venue":"AIDS Research and Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; ACT Government; York University; Tulane University; Bristol-Myers Squibb; University of Washington; University of Rochester; University of Southern California; Ohio State University","keywords":"Medicine; Antiretroviral therapy; Internal medicine; Clinical trial; Randomized controlled trial; Toxicity; Interleukin; Human immunodeficiency virus (HIV); Viral load; Immunology; Gastroenterology; Cytokine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003437516,0.001004701,0.0006920125,0.0003445292,0.0006115967,0.0009967695,0.0007006664,0.002345179,0.01430445],"category_scores_gemma":[0.002656569,0.0003552919,0.0009663371,0.0003811367,0.0004785497,0.0006191626,0.0004244595,0.002469704,0.001661959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006393364,"about_ca_system_score_gemma":0.001592331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007495132,"about_ca_topic_score_gemma":0.00215188,"domain_scores_codex":[0.9982916,0.001282812,0.00008450876,0.0001139696,0.00008184092,0.0001453055],"domain_scores_gemma":[0.9986494,0.0004200817,0.0003423175,0.0001377682,0.00007518326,0.000375297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8372701,0.006665489,0.004669605,0.001843118,0.0006666134,0.0003110153,0.0001519899,0.0008549882,0.007718119,0.001167231,0.02214585,0.1165358],"study_design_scores_gemma":[0.8749817,0.08678171,0.01411656,0.0006257515,0.000554216,0.0002762255,0.00004796094,0.001018245,0.001566912,0.001009472,0.01897316,0.0000481381],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.8818443,0.01391236,0.002039344,0.005040355,0.001661417,0.04596249,0.01007282,0.0005247953,0.03894209],"genre_scores_gemma":[0.93407,0.002733326,0.004125766,0.007467957,0.0007492842,0.03491035,0.006506202,0.00004814915,0.009388912],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.01430445,"threshold_uncertainty_score":0.04785317,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03795704294206537,"score_gpt":0.3681745876916406,"score_spread":0.3302175447495752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}